伴发细胞遗传学异常对HLA相合同种异体干细胞移植后单体7或7q缺失急性髓系白血病的影响
本研究纳入1109例接受HLA相合同种异体干细胞移植的伴-7/7q-急性髓系白血病患者,按伴发细胞遗传学异常分为5组,比较2年无白血病生存率等结局;结果提示不伴MK、abn(17p)或inv(3)者生存较好,而伴MK、-5/5q-、abn(17p)或inv(3)者预后差。
要点
- 移植后2年无白血病生存率和总生存率分别为30%和36%。
- 第1组(-7/7q-±复杂核型)首次缓解期2年无白血病生存率48%。
- 伴单体核型、-5/5q-、17p异常或inv(3)者移植后预后仍差。
核心结论
- 伴-7/7q-的AML患者接受HLA相合同种异体干细胞移植后约三分之一可获得持久缓解。
- 不伴MK、abn(17p)或inv(3)的-7/7q-(伴或不伴复杂核型)移植后生存较好。
- 伴MK、-5/5q-、abn(17p)或inv(3)的患者即使接受移植预后仍差。
研究设计与样本
- 研究纳入1109例接受HLA相合同种异体干细胞移植的伴-7/7q-急性髓系白血病患者。
- 按伴发细胞遗传学异常分为5组:第1组为-7/7q-±复杂核型,第2组为单体核型,第3组为-5/5q-,第4组为17p异常,第5组为inv(3)。
主要发现
- 总体移植后2年无白血病生存率为30%,总生存率为36%,非复发死亡率为20%。
- 首次缓解期2年无白血病生存率第1组48%、第2组36.4%、第3组28.4%、第4组19.1%、第5组17.3%(P < .001)。
- 多因素分析证实各组间差异显著。
关键数值与推荐
- 首次缓解期2年无白血病生存率第1组48%、第2组36.4%、第3组28.4%、第4组19.1%、第5组17.3%(P < .001)。
- 移植后2年无白血病生存率30%,总生存率36%,非复发死亡率20%。
临床怎么用
- 对伴-7/7q-的AML患者进行移植前细胞遗传学评估时,应关注是否合并MK、-5/5q-、abn(17p)或inv(3)。
- 合并上述高危异常者移植后预后仍差,需在临床决策中加以考量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monosomy 7 or deletion 7q (-7/7q-) is the most frequent adverse cytogenetic features reported in acute myeloid leukemia (AML), and is a common indication for allogeneic stem cell transplantation (SCT). Nevertheless, -7/7q- occurs frequently with other high-risk cytogenetic abnormalities such as complex karyotype (CK), monosomal karyotype (MK), monosomy 5 or deletion 5q (-5/5q-), 17p abnormalities (abn(17p)) or inversion of chromosome 3 (inv(3)), the presence of which may influence the outcomes after SCT. A total of 1109 patients were allocated to this study. Two-year probability of leukemia-free survival (LFS) and overall survival (OS) were 30% and 36%, respectively. Two-year probability of non-relapse mortality (NRM) was 20%. We defined five different cytogenetic subgroups: the "-7/7q- ± CK group- designated group1," the "MK group-designated group 2," the "-5/5q- group- designated group 3," the "abn(17p) group- designated group 4" and the "inv(3) group- designated group 5." The 2-year probability of LFS in first remission was 48% for group 1, 36.4% for group 2, 28.4% for group 3, 19.1% for group 4 and 17.3% for group 5, respectively (P < .001). Multivariate analysis confirmed those significant differences across groups. Note, SCT in -7/7q- AML provides durable responses in one third of the patients. The presence of -7/7q- with or without CK in the absence of MK, abn(17p) or inv(3) is associated with a better survival after SCT. On the contrary, addition of MK, -5/5q-, abn(17p) or inv(3) identifies a sub-group of patients with poor prognosis even after SCT.
引用
- Poiré X, Labopin M, Polge E, et al. The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. Am J Hematol. 2020. PMID: 31876307. doi:10.1002/ajh.25714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。